| Biolink (NO)–Evonik: investment, 201603 acquisition €na of MedPalett AS by Evonik from Biolink Group |
2016-03-03 |
| Grünenthal–Axxam: drug discovery services, 201603– collab to discover small moleucule lead structures to treat pain + inflammation |
2016-03-03 |
| Pulsar Photonics–High-Tech Gründerfonds: investment, 201603 seed financing from HTGF |
2016-03-02 |
| Cycle GmbH–Hamburg (govt): investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–High-Tech Gründerfonds: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–PERSON: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–SEVERAL: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Merck (DE)–EMBL: drug discovery, 201603–201902 collab research 3y with EMBL Heidelberg w focus on cancer metabolism |
2016-03-01 |
| Retina Implant–SEVERAL: investment, 201602 private equity funding round €26m from existing + new investors |
2016-02-29 |
| CPGR (ZA)–Thermo Fisher: mass spectrometer, 201602 supply existent Q Exactive MS system used for proteomics |
2016-02-26 |
| Blue Scientific–Accurion: laboratory instruments, 201602– distribution Nanofilm Technology + Halcyonics products in UK + Nordics by Blue Scientific |
2016-02-25 |
| Pronutria–Nestlé: investment, 201602 equity investment $42.5m by Nestlé Health Science |
2016-02-23 |
| Ergomed–MC Services: public relations, 201602 service existent for Ergomed plc |
2016-02-18 |
| MorphoSys–MC Services: public relations, 201602 service existent for MorphoSys AG |
2016-02-18 |
| Newron–MC Services: public relations, 201602 service existent for Newron Pharmaceuticals |
2016-02-18 |
| Strüngmann Group–MC Services: public relations, 201602 service existent for AiCuris Anti-infective Cures GmbH |
2016-02-18 |
| Transcend Medical–Novartis: investment, 201602 acquisition €na by Alcon |
2016-02-18 |
| Ipsen–3B Pharmaceuticals: radiopharmaceutical, 201602– license ww excl for radiopharmaceuticals in oncology |
2016-02-17 |
| Saphetor–Capricorn One: public relations, 201602 service existent for Saphetor SA |
2016-02-17 |
| Saphetor–SEVERAL: investment, 201602 seed financing round CHF1.2m from undisclosed investors |
2016-02-17 |
| Venture Valuation–Nasdaq OMX: press release distribution, 201602– collab integration of channel news in Biotechgate online directories |
2016-02-17 |
| Apogenix–Germany (govt): grant, 201602 BMBF grant €3m for developm of companion diagnostic w R-Biopharm for APG101 in glioblastoma |
2016-02-16 |
| Merck (DE)–Weizmann Institute: life sciences, 201602– collab 3y framework agreement research |
2016-02-16 |
| Novartis–Pfizer: biosimilar, 201602– Sandoz acquires rights to PF-06438179 (infliximab) in EEA which Pfizer had to divest after Hospira acquisition |
2016-02-12 |
| Curetis–Degroof Petercam: financial services, 201602– supply service liquidity provider to facilitate share trading on Euronext Brussels + Amsterdam |
2016-02-11 |
| Armo BioSciences–HBM: investment, 201602 private financing round Series C totalling $50m incl $10m from new investor HBM Healthcare Investments |
2016-02-10 |
| Armo BioSciences–SEVERAL: investment, 201602 private financing round Series C $50m from existent + new investors |
2016-02-10 |
| Hemovent–SEVERAL: investment, 201602 financing round Series A $6m led by MIG Verwaltungs AG |
2016-02-10 |
| Qiagen–10x Genomics: genomic technology, 201602– collab co-developm + co-marketing of NGS + single-cell biology + bioinformatics solutions |
2016-02-09 |
| Sophia Genetics–Swift Biosciences: molecular diagnostics, 201602– collab product integration offering combined MDx solutions in Europe |
2016-02-09 |
| Tollys–Riboxx: cancer drug, 201602– license ww excl to Apoxxim TLR3-ligand programme to Tollys |
2016-02-04 |
| Univ Rochester–Indivumed: tissue bank, 201602– collab 3y €na to establish UMRC-Indivumed tissue bank for cancer research |
2016-02-04 |
| Labiotech.eu–SEVERAL: investment, 201602 seed financing round low €6-digit led by WestTech Ventures |
2016-02-03 |
| SmartDyeLivery–SEVERAL: investment, 201602 seed financing from bm|t + Sparkasse Jena-Saale-Holzland |
2016-02-03 |
| Syngenta–ChemChina: investment, 201602– recommended cash acquisition offer valuing Syngenta at over $43b ANNOUNCED |
2016-02-03 |
| Evotec–Michael J Fox Foundation: grant, 201602 research grant for further developm of TargetaSN programme to treat Parkinson’s disease |
2016-02-02 |
| Medicxi Ventures–SEVERAL: investment, 201602 closing €210m of MV1 fund incl investments from GSK + JnJ Innovation JJDC |
2016-02-02 |
| Mission Therapeutics–Roche: investment, 201602 financing round totalling £60m incl returning co-investor Roche Venture Fund |
2016-02-02 |
| Mission Therapeutics–SEVERAL: investment, 201602 financing round £60m led by Imperial Innovations + new investor Woodford PCT |
2016-02-02 |
| Qiagen–CosmosID: bioinformatics, 201602– collab integration of CosmosID metagenomics analysis platform in CLC Genomics Workbench |
2016-02-02 |
| Alere–Abbott: investment, 201602– acquisition $5.8b equity value with $56/share ANNOUNCED |
2016-02-01 |
| InflaRx–MC Services: public relations, 201601 service existent by MC Services AG |
2016-01-28 |
| Medigene–Univ Lausanne: TCR technology, 201601– collab €na service by UNIL using NTAmer technology of TCMetrix |
2016-01-25 |
| Merck (US)–Affimed: cancer immunotherapy, 201601– collab €na clinical research combining AFM13 w pembrolizumab in Hodgkin lymphoma |
2016-01-25 |
| SeNostic–SEVERAL: investment, 201601 seed financing round led by HTGF |
2016-01-25 |
| RA-MAP Consortium–Protagen: biomarker discovery, 201601– collab Protagen joins RA-MAP Consortium contributing SeroTag platform for RA biomarker search |
2016-01-21 |
| Synoste–Evonik: investment, 201601 financing round Series A single-digit €n from Evonik + HTGF + Finnvera + Lifeline Ventures + business angels |
2016-01-21 |
| Synoste–High-Tech Gründerfonds: investment, 201601 financing round Series A single-digit €m from Evonik + HTGF + Finnvera + Lifeline Ventures + angels |
2016-01-21 |
| Synoste–SEVERAL: investment, 201601 financing round Series A single-digit €n from Evonik + HTGF + Finnvera + Lifeline Ventures + business angels |
2016-01-21 |
| Vasopharm–Hume Brophy: public relations, 201601 service existent by Hume Brophy |
2016-01-21 |
| Vasopharm–SEVERAL: investment, 201601 financing round €20m led by HeidelbergCapital + Entrepreneurs Fund + Fort Rock Capital |
2016-01-21 |
| City of Hope–Cevec: rec protein production technology, 201601– license €na to CAP GT technology to Beckman Research Institute |
2016-01-20 |
| PharmGenomics (DE)–SEVERAL: investment, 201601 financing round incl ISB + KfW + private investors |
2016-01-20 |
| Abviris–High-Tech Gründerfonds: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein |
2016-01-19 |
| Abviris–Schleswig-Holstein (govt): investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein |
2016-01-19 |
| Abviris–SEVERAL: investment, 201601 financing round mid six-digit € figure from HTGF + MBG Schleswig-Holstein |
2016-01-19 |
| Zespri–Metabolomic Discoveries: metabolomic services, 201601– supply service MS-based profiling of kiwi fruit using Flavour Profiler Technology |
2016-01-18 |
| Emerald Cleantech–Evonik: investment, 201601 existent investment in Emerald Cleantech Fund III by Evonik Venturing |
2016-01-15 |
| GRC SinoGreen–Evonik: investment, 201601 investment €na in GRC SinoGreen Fund III by Evonik Venturing |
2016-01-15 |
| Pangaea Ventures–Evonik: investment, 201601 existent investment in Pangaea Ventures Fund III by Evonik Venturing |
2016-01-15 |
| Ayoxxa–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme |
2016-01-13 |
| Pepperprint–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme |
2016-01-13 |
| Personal MedSystems–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme |
2016-01-13 |
| Sonormed–Germany (govt): business development, 201601– supply service support in US with German Accelerator Life Sciences programme |
2016-01-13 |
| Heartbeat Medical–DocCheck: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano |
2016-01-12 |
| Heartbeat Medical–High-Tech Gründerfonds: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano |
2016-01-12 |
| Heartbeat Medical–SEVERAL: investment, 201601 financing round high 6-figure € sum from HTGF + DockCheck Guano |
2016-01-12 |
| AB2 Bio–SEVERAL: investment, 201601 financing round Series B CHF21m ($21m) from existent + new investors |
2016-01-11 |
| AbVitro–Juno Therapeutics: investment, 201601 acquisition $78m in cash + 1.289m shares of Juno stock |
2016-01-11 |
| Array BioPharma–Qiagen: molecular companion diagnostics, 201601– collab master agreement developm + commercialisation of CDx for drugs |
2016-01-11 |
| Nestlé–Seres Therapeutics: microbiome-based drug, 201601– ww rights excl North America to SER-109+SER-262+SER-287 $120m upfront |
2016-01-11 |
| Novartis–Surface Oncology: cancer immunotherapy, 201601– collab + license up to $170m in upfront + equity + milestones for 4 pre-clinical programs |
2016-01-11 |
| Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders |
2016-01-11 |
| Tensha Therapeutics–Roche: investment, 201601– acquisition $115m upfront cash + $420m milestones |
2016-01-11 |
| Affymetrix–Thermo Fisher: investment, 201601–201603 acquisition of Affymetrix for $1.3b in cash |
2016-01-08 |
| Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix |
2016-01-07 |
| C4 Therapeutics–Roche: investment, 201601 financing round Series A totalling $73m incl lead investor Cobro Ventures + co-investor Roche |
2016-01-07 |
| C4 Therapeutics–SEVERAL: investment, 201601 financing round Series A $73m led by Cobro plus Cormorant + Kraft Group + EG Capital + Roche + Novartis |
2016-01-07 |
| Merck (DE)–Biocartis: molecular companion diagnostics, 201601– collab developm liquid biopsy Idylla RAS test RUO for mCRC |
2016-01-07 |
| Roche–C4 Therapeutics: drug discovery, 201601– collab up to >750m developm TPD therapeutics against Roche targets using Degronimid platform |
2016-01-07 |
| Biogen–Rodin Therapeutics: CNS drugs, 201601– collab multi-year around neural epigenetics incl investment by Biogen |
2016-01-06 |
| Rodin Therapeutics–SEVERAL: investment, 201601– preferred stock financing commitments totalling $17.3m from Altas Venture + Biogen |
2016-01-06 |
| BRAIN–MIG Fonds: investment, 201601 existent shareholding of 20% by MIG |
2016-01-05 |
| BRAIN–Oddo: investment banking, 201601– supply service Oddo Seydler is lead manager for IPO of BRAIN at FSE |
2016-01-05 |
| BRAIN–Putsch (Recaro): investment, 201601 existent shareholding of 51% by MP Betiligungs GmbH |
2016-01-05 |
| BRAIN–SEVERAL: investment, 201601–201602 IPO €32.5m net €31.5m w 3.5m+108k shares at €9/share at Frankfurt Stock Exchange |
2016-01-05 |
| Scholar Rock–SEVERAL: investment, 201601 financing round Series B $36m |
2016-01-04 |
| Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG |
2016-01-01 |
| MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems |
2016-01-01 |
| Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program |
2016-01-01 |
| Roche–Max Planck: drug discovery services, 201601–20812 collab LDC will act as translational incubator for small molecule projects w academic partners |
2016-01-01 |
| Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets |
2016-01-01 |
| UCB–Evotec: compound management, 201601–202012 supply service €na sample management for UCB by Evotec Toulouse |
2016-01-01 |
| Mo Bio Laboratories–Qiagen: investment, 2015Q4 acquisition by Qiagen |
2015-12-31 |
| Mologen–Bâloise: investment, 201512 existing investor Bâloise Holding holding estimated 6% in Mologen |
2015-12-31 |
| Mologen–Deutsche Balaton: investment, 201512 existing investor holding estimated 5% in Mologen |
2015-12-31 |
| Mologen–Global Derivative Trading: investment, 201512 existing investor Global Derivative Trading GmbH owns estimated 24% in Mologen |
2015-12-31 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 27 28 29 ... 55 56 57 
Date![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
